Work

Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group

Year: 2009

Type: article

Study designs: Randomized Controlled Trial, Clinical Trial

Source: Breast Cancer Research and Treatment

DOI: 10.1007/s10549-009-0498-7

Authors: Kenichi Inoue, Kazuhiko Nakagami, Mitsuhiro Mizutani, Yasuo Hozumi, Yasuhiro Fujiwara, Norikazu Masuda, Fumine Tsukamoto, Mitsue Saito, Shigeto Miura, Kenji Eguchi, Tetsu Shinkai, Masashi Ando, Toru Watanabe, Noriyuki Masuda, Yasuo Ohashi, Muneaki Sano, Shinzaburo Noguchi

Institutions: Saitama Cancer Center, Shizuoka General Hospital, Jichi Medical University, Osaka National Hospital, Kitasato University, Osaka Hospital, Juntendo University, Teikyo University, Shikoku Cancer Center, The University of Tokyo, The University of Osaka

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Chugai Pharmaceutical

OpenAlex ID: W2034414538

FWCI: 5.216

Cites: 14

Cited by: 90

Related to: 10